This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Safety Information

Updated on 15/03/2018

CARDIOVASCULAR

EZETROL is generally well tolerated when added to a statin, or as monotherapy1

In clinical studies:

  • Adverse events were usually mild and transient
  • The overall incidence of side effects and discontinuation rates were similar between EZETROL and placebo

Adding EZETROL to a statin has a similar adverse event profile to statin therapy alone.

  EZETROL monotherapy (n=2,396) vs. placebo (n=1,159) EZETROL co-administered with a statin (n=11,308) vs. statin alone (n=9,361)
Common
(≥1/100 to <1/10)
Abdominal pain, diarrhoea, flatulence, fatigue ALT and/or AST increased, headache, myalgia
Uncommon
(≥1/1,000 to <1/100)
ALT and/or AST increased, blood CPK increased, gamma-glutamyltransferase increased, liver fuction test abnomal, cough, dyspepsia, gastro-oesophageal reflux disease, nausea, arthralgia, muscle spasms, neck pain, decreased appetite, hot flush, hypertension, chest pain, pain Paraesthesia, dry mouth, gastritis, pruritus, rash, urticaria, back pain, muscular weakness, pain in extremity, asthenia, oedema peripheral

Adapted from EZETROL Summary of Product Characteristics.1

Please refer to SPC for full prescribing information.

Contraindications1

Hypersensitivity to the active substance or to any of the excipients.

When EZETROL is co-administered with a statin, please refer to the SPC for that particular medicinal product.

Therapy with EZETROL co-administered with a statin is contraindicated during pregnancy and lactation.

EZETROL co-administered with a statin is contraindicated in patients with active liver disease or unexplained persistent elevations in serum transaminases.

Special warnings1

When EZETROL is co-administered with a statin, please refer to the SPC for that particular medicinal product.

Liver enzymes

In controlled co-administration trials in patients receiving EZETROL with a statin, consecutive transaminase elevations (≥3 X the upper limit of normal [ULN]) have been observed. When EZETROL is co-administered with a statin, liver function tests should be performed at initiation of therapy and according to the recommendations of the statin.

In the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT), 18,144 patients with coronary heart disease and ACS event history were randomized to receive ezetimibe/simvastatin 10/40 mg daily (n=9067) or simvastatin 40 mg daily (n=9077). During a median follow-up of 6.0 years, the incidence of consecutive elevations of transaminases (≥3 X ULN) was 2.5% for ezetimibe/simvastatin and 2.3% for simvastatin.

In a controlled clinical study in which over 9000 patients with chronic kidney disease were randomized to receive EZETROL 10 mg combined with simvastatin 20 mg daily (n=4650) or placebo (n=4620), (median follow-up period of 4.9 years), the incidence of consecutive elevations of transaminases (>3 X ULN) was 0.7% for EZETROL combined with simvastatin and 0.6% for placebo.

Skeletal muscle

In post-marketing experience with EZETROL, cases of myopathy and rhabdomyolysis have been reported. Most patients who developed rhabdomyolysis were taking a statin concomitantly with EZETROL. However, rhabdomyolysis has been reported very rarely with EZETROL monotherapy and very rarely with the addition of EZETROL to other agents known to be associated with increased risk of rhabdomyolysis. If myopathy is suspected based on muscle symptoms or is confirmed by a creatine phosphokinase (CPK) level >10 times the ULN, EZETROL, any statin, and any of these other agents that the patient is taking concomitantly should be immediately discontinued. All patients starting therapy with EZETROL should be advised of the risk of myopathy and told to report promptly any unexplained muscle pain, tenderness or weakness.

In IMPROVE-IT, 18,144 patients with coronary heart disease and ACS event history were randomized to receive ezetimibe/simvastatin 10/40 mg daily (n=9067) or simvastatin 40 mg daily (n=9077). During a median follow-up of 6.0 years, the incidence of myopathy was 0.2% for ezetimibe/simvastatin and 0.1% for simvastatin, where myopathy was defined as unexplained muscle weakness or pain with a serum CK ≥10 times ULN or two consecutive observations of CK ≥5 and <10 times ULN. The incidence of rhabdomyolysis was 0.1% for ezetimibe/simvastatin and 0.2% for simvastatin, where rhabdomyolysis was defined as unexplained muscle weakness or pain with a serum CK ≥10 times ULN with evidence of renal injury, ≥5 times ULN and <10 times ULN on two consecutive occasions with evidence of renal injury or CK ≥10,000 IU/L without evidence of renal injury.

In a clinical trial in which over 9000 patients with chronic kidney disease were randomized to receive EZETROL 10 mg combined with simvastatin 20 mg daily (n=4650) or placebo (n=4620) (median follow-up 4.9 years), the incidence of myopathy/rhabdomyolysis was 0.2% for EZETROL combined with simvastatin and 0.1% for placebo.

Hepatic insufficiency

Due to the unknown effects of the increased exposure to ezetimibe in patients with moderate or severe hepatic insufficiency, EZETROL is not recommended.

Paediatric (6 to 17 years of age) patients

Efficacy and safety of EZETROL in patients 6 to 10 years of age with heterozygous familial or non-familial hypercholesterolemia have been evaluated in a 12-week controlled clinical trial. Effects of ezetimibe for treatment periods > 12 weeks have not been studied in this age group.

EZETROL has not been studied in patients younger than 6 years of age.

Efficacy and safety of EZETROL co-administered with simvastatin in patients 10 to 17 years of age with heterozygous familial hypercholesterolemia have been evaluated in a controlled clinical trial in adolescent boys (Tanner stage II or above) and in girls who were at least one year post-menarche.

In this limited controlled study, there was generally no detectable effect on growth or sexual maturation in the adolescent boys or girls, or any effect on menstrual cycle length in girls. However, the effects of ezetimibe for a treatment period > 33 weeks on growth and sexual maturation have not been studied.

The safety and efficacy of EZETROL co-administered with doses of simvastatin above 40 mg daily have not been studied in paediatric patients 10 to 17 years of age.

The safety and efficacy of EZETROL co-administered with simvastatin have not been studied in paediatric patients < 10 years of age.

The long-term efficacy of therapy with EZETROL in patients below 17 years of age to reduce morbidity and mortality in adulthood has not been studied.

Fibrates

The safety and efficacy of EZETROL administered with fibrates have not been established.

If cholelithiasis is suspected in a patient receiving EZETROL and fenofibrate, gallbladder investigations are indicated and this therapy should be discontinued.

Ciclosporin

Caution should be exercised when initiating EZETROL in the setting of ciclosporin. Ciclosporin concentrations should be monitored in patients receiving EZETROL and ciclosporin.

Anticoagulants

If EZETROL is added to warfarin, another coumarin anticoagulant, or fluindione, the International Normalised Ratio (INR) should be appropriately monitored.

Excipient

Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

Reference

  1. EZETROL Summary of Product Characteristics.

Supporting documentation

Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

CARD-1247023-0000 | Date of Preparation: March 2018